the differences in efficacy and safety between the vector vaccine ChAdOx1 nCoV-19/AZD1222 (Oxford-AstraZeneca) and mRNA-based vaccine mRNA-1273 (Moderna) in patients with AIRD, and to explore the cell-cell interactions between high and low anti-SARS-CoV-2 IgG levels in patients with ...
We evaluated two doses, 28 days apart, of ARCT-154, a self-amplifying mRNA COVID-19 vaccine, compared with saline placebo in an integrated phase 1/2/3a/3b controlled, observer-blind trial in Vietnamese adults (ClinicalTrial.gov identifier: NCT05012943). Primary safety and reactogenicity ...
Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389PubMedGoogle ScholarCrossref 11. Kildegaard H, Lund LC, Højlund M, Stensballe LG, Pottegård A. Risk of adverse events after covid-19 ...
et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439–2450 (2020). Article CAS PubMed Google Scholar Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021)....
Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine N Engl J Med, 384 (2021), pp. 403-416 CrossrefView in ScopusGoogle Scholar 26 FP Polack, SJ Thomas, N Kitchin, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine N Engl J Med, 383 (2020), pp. 2603-2615...
Article https://doi.org/10.1038/s41467-024-50802-2 Efficacy, immunogenicity and safety of CoronaVac® in children and adolescents aged 6 months to 17 years: a multicenter, randomized, double-blind, placebo- controlled phase III clinical trial Received: 22 November 2023 Accepted: 22 July 2024 ...
Celen MK, Altin S, Celik I, Bayindir Y, Karaoglan I, Yilmaz A, Ozkul A, Gur H, Unal S, CoronaVac Study G (2021) Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Tu...
Wu et al. BMC Infectious Diseases (2024) 24:234 https://doi.org/10.1186/s12879-023-08754-3 BMC Infectious Diseases RESEARCH Open Access Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta- analysis Xiaodi Wu1†, Ke Xu1†, Ping Zhan2, ...
et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2035389 (2020). Kaul, D. An overview of coronaviruses including the SARS-2 coronavirus—molecular biology, epidemiology and clinical implications. Curr. Med. Res. Pract. 10...
Article https://doi.org/10.1038/s41467-024-50802-2 Efficacy, immunogenicity and safety of CoronaVac® in children and adolescents aged 6 months to 17 years: a multicenter, randomized, double-blind, placebo- controlled phase III clinical trial Received: 22 November 2023 Accepted: 22 July 2024 ...